Celsion denies plans to sell BPH (benign prostatic hyperplasia) business
This article was originally published in Clinica
Celsion, formerly Cheung Laboratories, says it has no intention of selling its benign prostatic hyperplasia (BPH) business "at this time". The announcement was made in response to an unsolicited offer, which the Celsion management found "did not reflect a true and fair value" of the business.
You may also be interested in...
The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.